Astellas Institute for Regenerative Medicine (AIRM), Universal Cells, and Osaka University have entered into a research collaboration to develop innovative pluripotent stem cell-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease.
Universal Cells holds the rights to Universal Donor Cell (UDC) technology to create cell therapy products from pluripotent stem cells that have reduced risk of immune rejection by genetically modifying Human Leukocyte Antigen (HLA) using gene editing technology.
Under the terms of the agreement, the three parties aim to combine the cartilage tissue creation protocol established by Professor Noriyuki Tsumaki of (Graduate School of Frontier Biosciences / Premium Research Institute for Human Metaverse Medicine) the Department of Tissue Biochemistry and Molecular Biology, Graduate School of Medicine, Osaka University, a leading researcher in cartilage diseases, Universal Cells’ UDC technology, and AIRM’s exceptional R&D expertise in cell therapy, and jointly create an innovative cell therapy for intervertebral disc degenerative disease.
Yoshitsugu Shitaka, Ph.D., Chief Scientific Officer (CScO) of Astellas, said: “Astellas is committed to achieving our VISION of being ‘on the forefront of healthcare change, turning innovative science into VALUE for patients’. We hope to provide our cutting-edge UDC technology to academia and startups globally, and deliver next-generation cell therapies to patients. This partnership is an important step in the open innovation using UDC technology.”
Professor Noriyuki Tsumaki, M.D., Ph.D., (Graduate School of Frontier Biosciences / Premium Research Institute for Human Metaverse Medicine) Department of Tissue Biochemistry and Molecular Biology, Graduate School of Medicine, Osaka University, said: “We believe that our cartilage-like tissue has the potential to regenerate intervertebral discs. We hope that combining our research with Astellas’ UDC technology and R&D cell therapy system will accelerate and realize the development of regenerative therapies to treat intervertebral disc degenerative disease.”
